AI-enhanced Base Editing Access Program
Accelerating discovery with free evaluation services
Revvity and Profluent are opening access to next-generation base editing. Through the AI-enhanced Base Editing Access Program, selected researchers can receive complimentary evaluation services to assess the new AI-engineered adenine base editors integrated within Revvity’s modular
Pin-point™ base editing platform.
Our goal is simple: To empower therapeutic development teams to explore how modular, high-precision base editing can advance their programs - without the usual barriers to entry.
Who can apply
- Established or early-stage therapeutic R&D teams.
- Projects focused on gene or cell therapy development.
- Programs where adenine base editing could address a disease-relevant mutation or model.
What’s included
- Free evaluation services with the Pin-point platform and AI-enhanced adenine deaminase reagents (up to 4 target-specific configurations).
- Consultation with Revvity’s base editing scientists on target design and optimization.
- Data sharing and co-marketing opportunities (optional).
Why apply
- Expand your reach: Explore ABE targets representing ~45% more pathogenic variants.
- Gain control: Evaluate single-nucleotide precision and titratable safety benefits.
- Simplify access: One license. One partner. Expert support from start to finish.
- Get creative: Take the first step in understanding whether base editing can help to solve your biggest challenges.
- De-risk exploration: A low-risk way to evaluate advanced ABE and CBE strategies, including multiplex or combinatorial editing, using clinically-relevant, modular tools.
Disclaimer: Pin-point base editing reagents are available for research use only and are not for diagnostic use or direct administration into humans or animals. The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.
Click here for the terms and conditions
Terms and conditions
- Eligibility & Participation: Participation is open to organizations submitting a proposal for early access to Pin-point base editing adenine base editor (ABE) configuration evaluation services. Submission does not guarantee selection. Applications shall be submitted by the deadline.
- Selection Criteria: Proposals will be evaluated based on scientific merit, feasibility, and alignment with Revvity’s strategic interests. Final selection is at Revvity’s sole discretion. Revvity may contact applicants for further information.
- Campaign Offer: Selected applicants may receive:
- Base editing efficiency and specificity data for up to four (4) target-specific ABE configurations as measured by Sanger sequencing after transfection of synthetic base editing reagents in cultured cells, delivered as a service, and
- With a total estimated market value not exceeding USD $10,000.
- Confidentiality: All proposal submissions will be treated as confidential by Revvity. Revvity will not disclose proposal details to third parties without the applicant’s prior written consent, except as required by law.
- No Obligation: Participation in this program does not create any obligation on Revvity to enter into further collaboration, provide services, or offer commercial terms beyond those described herein.
- Modification & Termination: Revvity reserves the right to modify, suspend, or terminate the campaign at any time without prior notice.
